Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution

ACS Chemical Neuroscience

Volumn 4, Issue 3, 2013, Pages 475-485

  Mahmoudi, Morteza ^a   Quinlan Pluck, Fiona ^b   Monopoli, Marco P ^b   Sheibani, Sara ^c   Vali, Hojatollah ^d   Dawson, Kenneth A ^b   Lynch, Iseult ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ROYAL MILITARY COLLEGE OF CANADA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; amyloid beta; fibrillation; protein conformation; Superparamagnetic iron oxide nanoparticles

Indexed keywords

AMYLOID BETA PROTEIN; NANOCOATING; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

AQUEOUS SOLUTION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG COATING; DRUG SYNTHESIS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; SURFACE CHARGE;

AMYLOID; AMYLOID BETA-PEPTIDES; FERRIC COMPOUNDS; HUMANS; MAGNETITE NANOPARTICLES; NANOPARTICLES; PARTICLE SIZE; SOLUTIONS; UP-REGULATION; WATER;

EID: 84875545405     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300196n     Document Type: Article

References (74)

1. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function Nat. Neurosci. 8, 79-84
2. Walsh, D. M., Klyubin, I., Shankar, G. M., Townsend, M., Fadeeva, J. V., Betts, V., Podlisny, M. B., Cleary, J. P., Ashe, K. H., Rowan, M. J., and Selkoe, D. J. (2005) The role of cell-derived oligomers of abeta in alzheimer's disease and avenues for therapeutic intervention Biochem. Soc. Trans. 33, 1087-1090
3. Selkoe, D. J. (2002) Alzheimer s disease is a synaptic failure Science 298, 789-791
4. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klien, W. L. (1998) Diffusible, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453
5. Walsh, D., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo Nature 416, 535-539
6. Lansbury, P. T. J. (1997) Inhibition of amyloid formation: A strategy to delay the onset of Alzheimer's disease Curr. Opin. Chem. Biol. 1, 260-267
7. Walsh, D. M. and Selkoe, D. J. (2007) Abeta Oligomers a decade of discovery J. Neurochem. 101, 1172-1184
8. Nelson, R. and Eisenberg, D. (2006) Structural models of amyloid-like fibrils Adv. Protein Chem. 73, 235-282
9. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Margaret, M., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., and Teplow, D. B. (1999) Amyloid betaprotein fibrillogenesis. Structure and biological activity of protofibrillar intermediates J. Biol. Chem. 274, 25945-25952
10. Guo, M., Gorman, P. M., Rico, M., Chakrabartty, A., and Laurents, D. V. (2005) Charge substitution shows that repulsive electrostatic interactionsimpede the oligomerization of Alzheimer amyloid peptides FEBS Lett. 579, 3574-3578
11. Liu, R. T., McAllister, C., Lyubchenko, Y., and Sierks, M. R. (2004) Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation J. Neurosci. Res. 75, 162-171
12. Lowe, T. L., Strzelec, A., Kiessling, L. L., and Murphy, R. M. (2001) Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF Biochemistry 40, 7882-7889
13. Sidhartha, M. C., Hinke, M., Maarten, M., Meijer, E. W., David, V., Hilal, A. L., Frank, B., and Wiep, S. (2007) Branched KLVFF Tetramers strongly potentiate inhibition of beta-amyloid aggregation ChemBioChem 8, 1857-1864
14. Bett, C. K., Ngunjiri, J. N., Serem, W. K., Fontenot, K. R., Hammer, R. P., McCarley, R. L., and Garno, J. C. (2010) Structurea Activity Relationships in Peptide Modulators of Amyloid Protein Aggregation: Variation in Disubstitution Results in Altered Aggregate Size and Morphology ACS Chem. Neurosci. 1, 608-626
15. Norde, W. (2000) Physical Chemistry of Biological Interfaces (Baszkin, A. and Norde, W., Eds.), p 115, Marcel Dekker, New York.
16. Tjernberg, L. O., Callaway, D. J. E., Tjernberg, L. O., Hahne, S., Lilliehook, C., Terenius, L., Thyberg, J., and Nordstedt, C. (1999) A molecular model of Alzheimer amyloid b-peptide fibril formation J. Biol. Chem. 274, 12619-12625
17. Guo, M., Gorman, P. M., Rico, M., Chakrabartty, A., and Laurents, D. V. (2005) Charge substitution shows that repulsive electrostatic interactions impede the oligomerization of Alzheimer amyloid peptides FEBS Lett. 579, 3574-3578
18. Fraser, P. E., Nguyen, J. T., Surewicz, W. K., and Kirschner, D. A. (1991) pH-dependent structural transitions of Alzheimer amyloidpeptides Biophys. J. 60, 1190-1201
19. Laurent, S., Ejtehadi, M. R., Rezaei, M., Kehoe, P. G., and Mahmoudi, M. (2012) Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease RSC Adv. 2, 5008-5033
20. Fraser, P., McLachlan, D., Surewicz, W., Mizzenqq, C., Snow, A., Nguyen, J., and Kirschner, D. A. (1994) Conformation andfibrillogenesis of Alzheimer Ab peptides with selected substitution of charged residues J. Mol. Biol. 244, 64-73
21. Necula, M., Kayed, R., Milton, S., and labe, C. G. (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct J. Biol. Chem. 282, 10311-10324
22. Kim, J. E. and Lee, M. (2003) Fullerene inhibits betaamyloid peptide aggregation Biochem. Biophys. Res. Commun. 303, 576-579
23. Hashimoto, M., Shahdat, H. M., Katakura, M., Tanabe, Y., Gamoh, S., Miwa, K., Shimada, T., and Shido, O. (2009) Effects of docosahexaenoic acid on in vitro amyloid beta peptide 25-35 fibrillation Biochim. Biophys. Acta 1791, 289-296
24. Sun, Y., Zhang, G., Hawkes, C. A., Shaw, J. E., McLaurin, J., and Nitz, M. (2008) Synthesis of scylloinositol derivatives and their effects on amyloid beta peptide aggregation Bioorg. Med. Chem. 16, 7177-7184
25. Cohen, T., Frydman-Marom, A., Rechter, M., and Gazit, E. (2006) Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives Biochemistry 45, 4727-4735
26. Linse, S., Cabaleiro-Lago, C., Xue, W. F., Lynch, I., Lindman, S., Thulin, E., Radford, S. E., and Dawson, K. A. (2007) Nucleation of protein fibrillation by nanoparticles Proc. Natl. Acad. Sci. U.S.A. 104, 8691-8696
27. Wu, W. H., Sun, X., Yu, Y. P., Hu, J., Zhao, L., Liu, Q., Zhao, Y. F., and Li, Y. M. (2008) TiO2 nanoparticles promote beta-amyloid fibrillation in vitro Biochem. Biophys. Res. Commun. 373, 315-318
28. Klajnert, B., Cortijo-Arellano, M., Cladera, J., and Bryszewska, M. (2006) Influence of dendrimer's structure on its activity against amyloid fibril formation Biochem. Biophys. Res. Commun. 345, 21-28
29. Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Lindman, S., Minogue, A. M., Thulin, E., Walsh, D. M., Dawson, K. A., and Linse, S. (2008) Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles J. Am. Chem. Soc. 130, 15437-15443
30. Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Dawson, K. A., and Linse, S. (2010) Dual Effect of Amino Modified Polystyrene Nanoparticles on Amyloid β Protein Fibrillation ACS Chem. Neurosci. 1, 279-287
31. Mahmoudi, M., Hosseinkhani, H., Hosseinkhani, M., Broutry, S., Simchi, A., Journeay, W. S., Subramani, K., and Laurent, S. (2011) Magnetic Resonance Imaging Tracking of Stem Cells in Vivo Using Iron Oxide Nanoparticles as a Tool for the Advancement of Clinical Regenerative Medicine Chem. Rev. 111, 253-280
32. Mahmoudi, M., Milani, A. S., and Stroeve, P. (2010) Synthesis, surface architecture and biological response of superparamagnetic iron oxide nanoparticles for application in drug delivery: a review Int. J. Biomed. Nanosci. Nanotechnol. 1, 164-201
33. Mahmoudi, M. and Shokrgozar, M. A. (2012) Multifunctional stable fluorescent magnetic nanoparticles Chem. Commun. 48, 3957-3959
34. Mahmoudi, M., Simchi, A., and Imani, M. (2010) Recent Advances in Surface Engineering of Superparamagnetic Iron Oxide Nanoparticles for Biomedical Applications J. Iran. Chem. Soc. 7, S1-S27
35. Nighoghossian, N., Wiart, M., Cakmak, S., Berthezène, Y., Derex, L., Cho, T.-H., Nemoz, C., Chapuis, F., Tisserand, G.-L., Pialat, J.-B., Trouillas, P., Froment, J.-C., and Hermier, M. (2007) Inflammatory Response After Ischemic Stroke Stroke 38, 303-307
36. Saleh, A., Schroeter, M., Ringelstein, A., Hartung, H.-P., Siebler, M., Mödder, U., and Jander, S. (2007) Iron Oxide Particle-Enhanced MRI Suggests Variability of Brain Inflammation at Early Stages After Ischemic Stroke Stroke 38, 2733-2737
37. Dousset, V., Brochet, B., Deloire, M. S. A., Lagoarde, L., Barroso, B., Caille, J.-M., and Petry, K. G. (2006) MR Imaging of Relapsing Multiple Sclerosis Patients Using Ultra-Small-Particle Iron Oxide and Compared with Gadolinium Am. J. Neuroradiol. 27, 1000-1005
38. Tourdias, T., Roggerone, S., Filippi, M., Kanagaki, M., Rovaris, M., Miller, D. H., Petry, K. G., Brochet, B., Pruvo, J.-P., Radüe, E.-W., and Dousset, V. (2012) Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging Radiology 264, 225-233
39. Brambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kóňa, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., Gobbi, M., Nicolas, V., Scheper, W., Moghimi, S. M., Tvaroška, I., Couvreur, P., and Andrieux, K. (2012) PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Toward Engineering of Functional Nanomedicines for Alzheimer's Disease ACS Nano 6, 5897-5908
40. Mahmoudi, M., Sahraian, M. A., Shokrgozar, M. A., and Laurent, S. (2011) Superparamagnetic Iron Oxide Nanoparticles: Promises for Diagnosis and Treatment of Multiple Sclerosis ACS Chem. Neurosci. 2, 118-140
41. Mahmoudi, M., Sant, S., Wang, B., Laurent, S., and Sen, T. (2011) Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy Adv. Drug Delivery Rev. 63, 24-46
42. Mahmoudi, M., Stroeve, P., Milani, A. S., and Arbab, A. (2010) Superparamagnetic Iron Oxide Nanoparticles: Synthesis, Surface Engineering, Cytotoxicity and Biomedical Applications, Nova Science Publishers, Inc., ISBN: 978-1-61668-964-3.
43. Skaat, H., Belfort, G., and Margel, S. (2009) Synthesis and characterization of fluorinated magnetic core-shell nanoparticles for inhibition of insulin amyloid fibril formation Nanotechnology 20, 225106
44. Skaat, H., Sorci, M., Belfort, G., and Margel, S. (2009) Effect of maghemite nanoparticles on insulin amyloid fibril formation: selective labeling, kinetics, and fibril removal by a magnetic field J. Biomed. Mater. Res., Part A 91, 342-351
45. Skaat, H. and Margel, S. (2009) Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-β fibrils detection and removal by a magnetic field Biochem. Biophys. Res. Commun. 386, 645-649
46. Viktor Andersson, B., Skoglund, C., Uvdal, K., and Solin, N. (2012) Preparation of amyloid-like fibrils containing magnetic iron oxide nanoparticles: Effect of protein aggregation on proton relaxivity Biochem. Biophys. Res. Commun. 419, 682-686
47. 4 magnetic nanoparticles on lysozyme amyloid aggregation Nanotechnology 21, 065103
48. Mahmoudi, M., Hofmann, H., Rothen-Rutishauser, B., and Petri-Fink, A. (2012) Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles Chem. Rev. 112, 2323-2338
49. Rauch, J., Kolch, W., and Mahmoudi, M. (2012) Cell Type-Specific Activation of AKT and ERK Signaling Pathways by Small Negatively-Charged Magnetic Nanoparticles Sci. Rep. 2, 868
50. Mahmoudi, M. and Serpooshan, V. (2012) Silver-Coated Engineered Magnetic Nanoparticles Are Promising for the Success in the Fight against Antibacterial Resistance Threat ACS Nano. 6, 2656-2664
51. Ikeda, K., Okada, T., Sawada, S.-i., Akiyoshi, K., and Matsuzaki, K. (2006) Inhibition of the formation of amyloid β-protein fibrils using biocompatible nanogels as artificial chaperones FEBS Lett. 580, 6587-6595
52. Olmedo, I., Araya, E., Sanz, F., Medina, E., Arbiol, J., Toledo, P., álvarez-Lueje, A., Giralt, E., and Kogan, M. J. (2008) How Changes in the Sequence of the Peptide CLPFFD-NH2 Can Modify the Conjugation and Stability of Gold Nanoparticles and Their Affinity for β-Amyloid Fibrils Bioconjugate Chem. 19, 1154-1163
53. Kirschner, D. A., Inouye, H., Duffy, L. K., Sinclair, A., Lind, M., and Selkoe, D. J. (1987) Synthetic peptide homologous to protein from Alzheimer disease forms amyloid-like fibrils in vitro Proc. Natl. Acad. Sci. U.S.A. 84, 6953-6957
54. Tjernberg, L. O., Naslund, J., Lindqvist, F., Johansson, J., Karlstrom, A. R., Thyberg, J., Terenius, L., and Nordstedt, C. (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand J. Biol. Chem. 271, 8545-8548
55. Gordon, D. J., Sciarretta, K. L., and Meredith, S. C. (2001) Inhibition of β-amyloid(40) fibrillogenesis and disassembly of β-amyloid(40) fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues Biochemistry 40, 8237-8245
56. Gordon, D. J., Tappe, R., and Meredith, S. C. (2002) Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits A. beta.1-40 fibrillogenesis J. Pept. Res. 60, 37-55
57. Gordon, D. J. and Meredith, S. C. (2003) Probing the role of backbone hydrogen bonding in β-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions Biochemistry 42, 475-485
58. Bieschke, J., Siegel, S. J., Fu, Y. W., and Kelly, J. W. (2008) Alzheimer's Aβ peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity. Evidence for a common lowabundance toxic structure(s) Biochemistry 47, 50-59
59. Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Dawson, K. A., and Linse, S. (2010) Dual Effect of Amino Modified Polystyrene Nanoparticles on Amyloid β Protein Fibrillation ACS Chem. Neurosci. 1, 279-287
60. Etienne, M. A., Aucoin, J. P., Fu, Y. W., McCarley, R. L., and Hammer, R. P. (2006) Stoichiometric inhibition of amyloid beta-protein aggregation with peptides containing alternating R,R-disubstituted amino acids J. Am. Chem. Soc. 126, 3522-3523
61. Amiri, H., Wan, S., Mahmoudi, M., Lascialfari, A., Lynch, I., and Monopoli, M. P. Protein Corona Affects Relaxivity and MRI Contrast Efficiency of Magnetic Nanoparticles. J. Nanopart. Res. 2012, not supplied.
62. Beckmann, N., Gérard, C., Abramowski, D., Cannet, C., and Staufenbiel, M. (2011) Noninvasive Magnetic Resonance Imaging Detection of Cerebral Amyloid Angiopathy-Related Microvascular Alterations Using Superparamagnetic Iron Oxide Particles in APP Transgenic Mouse Models of Alzheimer's Disease: Application to Passive Aβ Immunotherapy J. Neurosci. 31, 1023-1031
63. Vinters, H. V., Natté, R., Maat-Schieman, M. L. C., van Duinen, S. G., Hegeman-Kleinn, I., Welling-Graafland, C., Haan, J., and Roos, R. A. C. (1998) Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D) Acta Neuropathol. 95, 235-244
64. El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., and Luster, A. D. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease Nat. Med. 13, 432-438
65. Hickman, S. E. and Khoury, J. E. (2010) Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease NS Neurol. Disord.: Drug Targets 9, 168-173
66. Usher, T. C. and Wallis, S. H. (2004) Process of Making Carboxilated Dextran, U.S. Patent US6 703 499.
67. Martwiset, S., Koh, A. E., and Chen, W. (2006) Nonfouling Characteristics of Dextran-Containing Surfaces Langmuir 22, 8192-8196
68. Saboktakin, M. R., Tabatabaie, R. M., Maharramov, A., and Ramazanov, M. A. (2010) A synthetic macromolecule as MRI detectable drug carriers: Aminodextran-coated iron oxide nanoparticles Carbohydr. Polym. 80, 695-698
69. Mahmoudi, M., Simchi, A., Milani, A. S., and Stroeve, P. (2009) Cell toxicity of superparamagnetic iron oxide nanoparticles J. Colloid Interface Sci. 336, 510-518
70. Mahmoudi, M., Simchi, A., Imani, M., Milani, A. S., and Stroeve, P. (2008) Optimal design and characterization of superparamagnetic iron oxide nanoparticles coated with polyvinyl alcohol for targeted delivery and imaging J. Phys. Chem. B 112, 14470-14481
71. Betts, V., Leissring, M. A., Dolios, G., Wang, R., Selkoe, D. J., and Walsh, D. M. (2008) Aggregation and catabolism of disease-associated intra-A beta mutations: Reduced proteolysis of A beta A21G by neprilysin Neurobiol. Dis. 31, 442-450
72. Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V. N., and Fink, A. L. (2001) Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism Biochemistry 40, 6036-6046
73. Kodaka, M. (2004) Requirements for generating sigmoidal time-course aggregation in nucleation-dependent polymerization model Biophys. Chem. 107, 243-253
74. Mahmoudi, M., Sardari, S., Shokrgozar, M. A., Laurent, S., and Stroeve, P. (2011) Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles Nanoscale 3, 1127-1138